From "heartache" to "unable to breathe", and a brief analysis of the advantages of hs-cTn
- Categories:Academic exchanges
- Author:
- Origin:
- Time of issue:2021-05-26
- Views:0
(Summary description)"China Cardiovascular Disease Report 2019" shows that cardiovascular disease has become the primary cause of all-cause death in China. There are many types of diseases, and the onset is often acute and severe. In the golden time of rescue, timely diagnosis and clinical intervention are required. The urgency and necessity are much higher than other diseases. Cardiovascular-related biomarkers play an important role in this link, with the most prominent needs for the diagnosis of myocardial infarction and heart failure.
From "heartache" to "unable to breathe", and a brief analysis of the advantages of hs-cTn
(Summary description)"China Cardiovascular Disease Report 2019" shows that cardiovascular disease has become the primary cause of all-cause death in China. There are many types of diseases, and the onset is often acute and severe. In the golden time of rescue, timely diagnosis and clinical intervention are required. The urgency and necessity are much higher than other diseases. Cardiovascular-related biomarkers play an important role in this link, with the most prominent needs for the diagnosis of myocardial infarction and heart failure.
- Categories:Academic exchanges
- Author:
- Origin:
- Time of issue:2021-05-26
- Views:0
Scan the QR code to read on your phone
Download Attachment
Related News
-
[Consensus Interpretation] Clinical tests such as blood serum, folic acid, and vitamin B12 can be carried out to clarify the cause of the elevated blood serum
Hyperhomocysteinemia is closely related to the occurrence and development of various diseases, such as cardiovascular and cerebrovascular diseases, hypertension, diabetes, kidney disease, pregnancy and other diseases, and affects almost every organ in the body. A variety of mechanisms, such as chemical and sulfur-containing compounds abnormal metabolism, affect cell function, protein synthesis and regulation, and then lead to pathological changes in tissues and organs. The causes of abnormal total homocysteine metabolism are closely related to genes, nutrition, diseases, etc. The "Expert Consensus on Diagnosis and Treatment of Hyperhomocysteinemia" published in the "Electronic Journal of Tumor Metabolism and Nutrition" on September 9, 2020 》Based on a retrospective analysis of domestic and foreign research literature and evidence-based medicine in the past 30 years, combined with the characteristics of the Chinese population, the definition of hyperhomocysteinemia is given, and the dietary structure and/or the use of dietary supplements to reduce homocysteine levels is proposed. Recommendations for cysteine levels and the development of homocysteine-related testing indicators to clarify the cause of elevated homocysteine, and then guide precise clinical interventions to effectively improve homocysteine levels. To achieve the purpose of preventing disease occurrence or delaying disease progression. - [World Heart Day] Pay attention to heart health, care more with hearts 2021-09-29
- Three things about myocardial infarction 2021-09-10
- [Consensus Interpretation] To protect the health of expectant mothers, Tianchen provides integrated solutions for all-scenario applications 2021-08-11
- Those things about 25-0H-VD 2021-06-30
- The thing about H-FABP 2021-06-18
Follow Tiachen
Tel:
-
Add: 301, Block A, Building #1, Phase 2, Gaoxinqi Industrial Zone, 1st Liuxian Road, Bao’an District, Shenzhen
-
Add:3rd Floor, Building B, Youlitong Technology Park, No. 56 Qingsong Road, Pingshan District, Shenzhen
© COPYRIGHT 2022 Shenzhen Tiachen Medical Technology Co., Ltd.. ALL RIGHTS RESERVED 粤ICP备19151424号 SEO
Follow Tiachen
-
Tel:0755-86713679
-
Add: 301, Block A, Building #1, Phase 2, Gaoxinqi Industrial Zone, 1st Liuxian Road, Bao’an District, Shenzhen
-
Add:3rd Floor, Building B, Youlitong Technology Park, No. 56 Qingsong Road, Pingshan District, Shenzhen
Copyright: Shenzhen Tiachen Medical Technology Co., Ltd., 粤ICP备19151424号